People News: Sudler & Hennessey, Presidio Pharmaceuticals, Reglera and Decisions Resources
Presidio Pharmaceuticals hired Eric Ruby as VP of regulatory affairs. Ruby previously served as senior director, regulatory affairs at Alnylam Pharmaceuticals and, prior to Alnylam, led regulatory communications and filings at Vertex Pharmaceuticals for HCV drug telaprevir. He also served with the FDA for eight years.
Regulatory consulting firm Reglera is hiring Martha Wells, a former FDA branch chief, later this year upon her retirement from the agency. She will serve as VP of regulatory affairs for tissue and biologics. Wells has spent 36 years working for the FDA and was formerly chief of the Human Tissues and Reproduction Branch, Division of Human Tissues, Office of Cellular, Tissue and Gene Therapies within the Center for Biologics Evaluation and Research.
Decision Resources promoted Mark Bard to chief commercial officer. He had been president of Manhattan Research, which was bought by Decision Resources in 2008. Replacing Bard as president of Manhattan Research is Joe Farris. Other promotions within the company include Jason LaBonte, PhD, who was promoted to chief operating officer of Decision Resource's newly formed Biopharma Portfolio Planning segment, and Matthew Bonner, MD, who was appointed VP of research. Elizabeth Marshall was promoted to VP of marketing.